戻る Agenda
LS03: 5 Industry Group Joint Session:New Options in Clinical Trial Operation Model?DCT & Remote Utilization (Part 1)
Session Chair(s)
Hiroshi Matsuzawa, MSc
Clinical Development
Astellas Pharma Inc., Japan
Toshiharu Sano, RPh
Vice-Chairperson, Drug Evaluation Committee
Japan Pharmaceutical Manufacturers Association, Japan
Speaker(s)
Ai Nakamura
R&D Head Club, Japan
Performance Working Group Member
Takeshi Hashimoto, MPharm
Novartis Pharma K.K., Japan
Co-leader
Masahito Yamanaka
EFPIA (Bayer Yakuhin, Ltd.), Japan
Taskforce Member
Junichi Tanokashira
Japan Pharmaceutical Manufacturers Association (JPMA), Japan
Clinical Evaluation Expert Committee, Drug Evaluation Committee